ITGA1 and Parkinson disease: Collectively, these findings establish microglial CD49a-targeted therapy as a novel therapeutic paradigm for PD, positioning obtustatin as a promising clinical candidate with demonstrable translational potential across neuroinflammatory and neurodegenerative disorders.